Back to Search
Start Over
Right Heart Failure After Left Ventricular Assist Device Implantation in Patients With Chronic Congestive Heart Failure
Right Heart Failure After Left Ventricular Assist Device Implantation in Patients With Chronic Congestive Heart Failure
- Source :
- The Journal of Heart and Lung Transplantation. 25:1-6
- Publication Year :
- 2006
- Publisher :
- Elsevier BV, 2006.
-
Abstract
- Background Right heart failure (RHF) is not an infrequent complication of left ventricular assist device (LVAD) implantation. Few studies have examined outcomes for LVAD patients who subsequently develop RHF. This study details one center's experience with RHF in chronic congestive heart failure (CHF) patients. Methods One hundred eight patients with chronic CHF (≥6 months) who underwent HeartMate LVAD implantation were identified during June 1996 to July 2004. Acute heart failure patients requiring LVADs were excluded to eliminate the impact of confounding non-cardiac factors. RHF was defined as the need for a subsequent right ventricular assist device (RVAD), ≥14 days of intravenous inotropes/pulmonary vasodilators, or both. Forty-two (38.9%) RHF patients were identified. Fourteen of these required RVAD insertion. Outcome parameters included early (≤30-day) mortality, intensive care unit (ICU) length of stay (LOS), incidence of re-operation for bleeding and acute renal failure, and stroke, bridge-to-transplantation rate and post-transplantation survival rate. Results More female patients developed RHF than not (73.3% vs 26.7%, p = 0.003). RHF patients had a higher early mortality rate, greater ICU LOS, higher rates of re-operation for bleeding and renal failure, and lower bridge-to-transplantation rate than non-RHF patients (19.0% vs 6.2%, p = 0.039; 23.8 ± 23.7 vs 9.6 ± 7.1 days, p p = 0.026; 61.0% vs 22.6%, p p = 0.003; respectively). Fourteen (33.3%) RHF patients required RVAD insertion. Elevated intra-operative central venous pressure (CVP) was found to be an independent predictor of post-LVAD RHF. Overall bridge-to-transplantation rate for the entire study cohort was 73.1%. Conclusions The development of RHF after LVAD insertion confers significant morbidity and mortality. Judicious application of inotropes and pulmonary vasodilators and timely RVAD insertion, if necessary, should be maintained. Further investigations evaluating pre- and intra-operative risk factors for the development of RHF are warranted.
- Subjects :
- Adult
Male
Pulmonary and Respiratory Medicine
medicine.medical_specialty
Heart disease
Ventricular Dysfunction, Right
medicine.medical_treatment
law.invention
Ventricular Dysfunction, Left
Sex Factors
law
Artificial heart
Internal medicine
medicine
Humans
Survival rate
Retrospective Studies
Heart Failure
Transplantation
business.industry
Mortality rate
Central venous pressure
Middle Aged
medicine.disease
Survival Analysis
Intensive care unit
Treatment Outcome
Ventricular assist device
Heart failure
Chronic Disease
Cardiology
Female
Surgery
Heart-Assist Devices
Cardiology and Cardiovascular Medicine
business
Subjects
Details
- ISSN :
- 10532498
- Volume :
- 25
- Database :
- OpenAIRE
- Journal :
- The Journal of Heart and Lung Transplantation
- Accession number :
- edsair.doi.dedup.....c2d57954df76ed6de67c7e9a0fa05d37
- Full Text :
- https://doi.org/10.1016/j.healun.2005.07.008